Show simple item record

dc.contributor.authorTrouiller, P
dc.contributor.authorTorreele, E
dc.contributor.authorOlliaro, P
dc.contributor.authorWhite, N J J
dc.contributor.authorFoster, S
dc.contributor.authorWirth, D
dc.contributor.authorPécoul, B
dc.date.accessioned2008-05-27T14:09:32Z
dc.date.available2008-05-27T14:09:32Z
dc.date.issued2001-11
dc.identifier.citationDrugs for neglected diseases: a failure of the market and a public health failure? 2001, 6 (11):945-51 Trop. Med. Int. Healthen
dc.identifier.issn1360-2276
dc.identifier.pmid11703850
dc.identifier.urihttp://hdl.handle.net/10144/28439
dc.description.abstractInfectious diseases cause the suffering of hundreds of millions of people, especially in tropical and subtropical areas. Effective, affordable and easy-to-use medicines to fight these diseases are nearly absent. Although science and technology are sufficiently advanced to provide the necessary medicines, very few new drugs are being developed. However, drug discovery is not the major bottleneck. Today's R&D-based pharmaceutical industry is reluctant to invest in the development of drugs to treat the major diseases of the poor, because return on investment cannot be guaranteed. With national and international politics supporting a free market-based world order, financial opportunities rather than global health needs guide the direction of new drug development. Can we accept that the dearth of effective drugs for diseases that mainly affect the poor is simply the sad but inevitable consequence of a global market economy? Or is it a massive public health failure, and a failure to direct economic development for the benefit of society? An urgent reorientation of priorities in drug development and health policy is needed. The pharmaceutical industry must contribute to this effort, but national and international policies need to direct the global economy to address the true health needs of society. This requires political will, a strong commitment to prioritize health considerations over economic interests, and the enforcement of regulations and other mechanisms to stimulate essential drug development. New and creative strategies involving both the public and the private sector are needed to ensure that affordable medicines for today's neglected diseases are developed. Priority action areas include advocating an essential medicines R&D agenda, capacity-building in and technology transfer to developing countries, elaborating an adapted legal and regulatory framework, prioritizing funding for essential drug development and securing availability, accessibility, distribution and rational use of these drugs.
dc.language.isoenen
dc.publisherWiley-Blackwellen
dc.rightsArchived on this site with the kind permission of Wiley-Blackwell, [url]http://www.blackwell-synergy.com/loi/tmi[/url]en
dc.subject.meshCommunicable Diseases, Emergingen
dc.subject.meshDrug and Narcotic Controlen
dc.subject.meshHealth Care Sectoren
dc.subject.meshHealth Policyen
dc.subject.meshHealth Prioritiesen
dc.subject.meshHealth Services Accessibilityen
dc.subject.meshHealth Services Needs and Demanden
dc.subject.meshHumansen
dc.subject.meshLegislation, Drugen
dc.subject.meshResearchen
dc.subject.meshWorld Healthen
dc.titleDrugs for neglected diseases: a failure of the market and a public health failure?en
dc.contributor.departmentCentre Hospitalier Universitaire de Grenoble, Grenoble, France.en
dc.identifier.journalTropical Medicine & International Healthen
refterms.dateFOA2019-03-04T10:30:37Z
html.description.abstractInfectious diseases cause the suffering of hundreds of millions of people, especially in tropical and subtropical areas. Effective, affordable and easy-to-use medicines to fight these diseases are nearly absent. Although science and technology are sufficiently advanced to provide the necessary medicines, very few new drugs are being developed. However, drug discovery is not the major bottleneck. Today's R&D-based pharmaceutical industry is reluctant to invest in the development of drugs to treat the major diseases of the poor, because return on investment cannot be guaranteed. With national and international politics supporting a free market-based world order, financial opportunities rather than global health needs guide the direction of new drug development. Can we accept that the dearth of effective drugs for diseases that mainly affect the poor is simply the sad but inevitable consequence of a global market economy? Or is it a massive public health failure, and a failure to direct economic development for the benefit of society? An urgent reorientation of priorities in drug development and health policy is needed. The pharmaceutical industry must contribute to this effort, but national and international policies need to direct the global economy to address the true health needs of society. This requires political will, a strong commitment to prioritize health considerations over economic interests, and the enforcement of regulations and other mechanisms to stimulate essential drug development. New and creative strategies involving both the public and the private sector are needed to ensure that affordable medicines for today's neglected diseases are developed. Priority action areas include advocating an essential medicines R&D agenda, capacity-building in and technology transfer to developing countries, elaborating an adapted legal and regulatory framework, prioritizing funding for essential drug development and securing availability, accessibility, distribution and rational use of these drugs.


Files in this item

Thumbnail
Name:
Access Trouiller TMIH 2001.pdf
Size:
134.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record